Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

4 Pharma Stocks to Buy Now for the Long Haul

The pharma industry has experienced tremendous growth in recent years. The industry should continue to grow, driven by the growing market for personalized medicine and e-pharmacies. Hence, pharma stocks Pfizer (PFE), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and Zoetis (ZTS) might be worth buying for the long term. Also, these companies…

StockNews.com

New door-to-door pharmacy delivery app promises to make London life less painful

It’s like shopping at Boots on your phone with the meds biked to your home in minutes.

Evening Standard

Pharmacy contraceptive pill trial a 'band-aid solution'

The health minister welcomes a proposed trial to allow pharmacists to prescribe the contraceptive pill but doctors' groups have criticised the move.

AAP

From analysis to the latest developments in health,
read the most diverse news in one place.

The 3 Best Pharma Stocks to Buy for Big Gains in 2023

The pharma industry witnessed solid growth amid the pandemic. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth over the coming years. Therefore, investors could consider buying fundamentally sound pharma stocks Johnson & Johnson (JNJ), AbbVie (ABBV), and…

StockNews.com

The big business of clogged arteries

Medtronic, the world’s largest medical device company, allegedly "groomed" doctors to overuse its vascular products

Salon

Moderna, Pfizer and BioNTech Covid vaccine patent dispute heads to 2024 trial

US firm Moderna is suing its competitors for alleged patent infringement in relation to their Comirnaty vaccine.

The Independent UK

The No. 1 Pharma Stock to Buy for the Long Haul

Despite lingering macro disruptions, Street analysts expect pharma stock Pfizer (PFE) to gain double digits in the near term. Moreover, it pays a reliable dividend. Given its robust fundamentals, I think PFE might be an ideal buy for the long haul. Keep reading.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

FDA panel weighs moving opioid antidote over the counter

U.S. health advisers are weighing whether the overdose-reversal drug naloxone should be made available as an over-the-counter medication

The Independent UK

Prepping for a new post-Roe reality

A decision on a lawsuit in Texas could lead to nationwide mifepristone ban

Salon

The administration's next crack at lower drug prices

The Biden administration unveiled three drug payment programs Tuesday aimed at helping reduce patients' out-of-pocket costs.

Axios

Edinburgh-based health tech company Clevermed acquired by hospital software specialist System C

Move will support growth of flagship product BadgerNet,

Insider UK

CSL grows first-half profit 10pct to $2.6 billion

CSL has beaten first-half earnings expectations thanks to its vaccine business and contributions from its new iron deficiency therapy company.

AAP

The Best Stock to Invest $1,000 in Right Now

Pfizer (PFE) played a pivotal role in developing vaccines and pills that helped the world return to normal from the COVID-19 pandemic. The company reported record revenue and earnings in fiscal 2022. Given the company’s solid growth prospects, it could be wise to invest in the stock right now. Keep…

StockNews.com

40 million would lose abortion access if court blocks pill, study shows

163% more women would lose access to abortion care if the FDA's approval of mifepristone is revoked.

Axios

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Take AstraZeneca’s warning seriously. The UK is missing out in life sciences

Big pharma has choices about where to make new investments and, increasingly it seems, it is not choosing Britain

Chicago Sun-Times

Centene Corp. settles for $215 million on California Medicaid overbilling accusations

More than 20 states are investigating or have investigated Centene’s Medicaid pharmacy billing. The company also has agreed to pay settlements to at least 16 other states, including Illinois and Indiana.

Newsroom.co.nz

Pharmac to get one-time $66m boost

The national drug-buying agency will get an extra $66 million in 2023 in a one-off cash injection, according to documents reviewed by Newsroom.

Birmingham Post

Shield Therapeutics revenues boosted by US sales of iron deficiency pills

The pharmaceuticals firm recently joined forced with Pennsylvania-based Viatris to tackle the American market

Get all your
news in one place.

100’s of premium titles.
One news app.

Chicago Sun-Times

CVS buys Chicago-based Oak Street Health for $10.6B

Oak Street Health runs primary care centers mostly for lower-to-middle income people with Medicare Advantage plans.

Insider UK

Glasgow biopharmaceuticals firm hires new chief executive

University spin-out takes on new leadership as it looks towards international growth

StockNews.com

1 Medical Stock to Get Bullish on Right Now

Medical stock Zoetis (ZTS) has witnessed steady growth despite the market turbulence in the past few months. Moreover, Wall Street analysts expect the stock to soar further. So, considering its robust fundamentals, ZTS might be worth buying now. Keep reading.

The Guardian - UK

Pfizer’s Susan Rienow: from Covid to fighting the ‘silent pandemic’

The pharma giant’s UK chief is adding the company’s voice to scientists’ warnings of the dangers of antibacterial resistance

Insider UK

Nodus Oncology secures £2.4 million investment

Edinburgh-based start-up will now be able to accelerate development of its life sciences technology

Daily Record

Workers resume strike action as union admit dispute could drag on

Unite chiefs say their members are determined to get 'what they are owed' in bonus payments row.

StockNews.com

Want to Get Richer in 2023? Try This Medical Stock

Mckesson Corporation (MCK) delivered better-than-expected earnings for the last quarter and updated its outlook for fiscal 2023. Wall Street analysts expect the stock to rise more than 18% in the near term. Therefore, it could be wise to buy this medical stock now. Read more….

1 … 52 53 54 55

People

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.